{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:42:50Z","timestamp":1791218570246,"version":"4.1.0"},"reference-count":190,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"am","delay-in-days":324,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["P30 ES026529"],"award-info":[{"award-number":["P30 ES026529"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jconrel.2025.114028","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T15:59:51Z","timestamp":1752767991000},"page":"114028","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Nanocarrier drug delivery systems for gynecological cancer therapeutics"],"prefix":"10.1016","volume":"385","author":[{"given":"Jordan D.","family":"Berezowitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany E.","family":"Givens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2025.114028_bb0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jconrel.2014.03.054","article-title":"Controlled drug delivery systems: past forward and future back","volume":"190","author":"Park","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114028_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e17488","article-title":"Advances in drug delivery systems, challenges and future directions","volume":"9","author":"Ezike","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.jconrel.2025.114028_bb0015","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.msec.2019.01.066","article-title":"Employment of enhanced permeability and retention effect (EPR): nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer","volume":"98","author":"Kalyane","year":"2019","journal-title":"Mater. Sci. Eng. C Mater. Biol. Appl."},{"key":"10.1016\/j.jconrel.2025.114028_bb0020","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0168-3659(99)00248-5","article-title":"Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review","volume":"65","author":"Maeda","year":"2000","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114028_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2020.100970","article-title":"Investigating the EPR effect of nanomedicines in human renal tumors perfusion strategy","volume":"35","author":"Ding","year":"2020","journal-title":"Nano Today"},{"key":"10.1016\/j.jconrel.2025.114028_bb0030","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jconrel.2022.03.043","article-title":"Strategies to improve the EPR effect: a mechanistic perspective and clinical translation","volume":"345","author":"Ikeda-Imafuku","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114028_bb0035","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.2147\/IJN.S168053","article-title":"Recent advances in \u201csmart\u201d delivery systems for extended drug release in cancer therapy","volume":"13","author":"Kalaydina","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.jconrel.2025.114028_bb0040","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.3390\/polym11091441","article-title":"Engineered polymeric materials for biological applications: overcoming challenges of the bio-Nano Interface","volume":"11","author":"Simpson","year":"2019","journal-title":"Polymers (Basel)"},{"key":"10.1016\/j.jconrel.2025.114028_bb0045","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1557\/s43577-022-00389-0","article-title":"Biomaterials science and engineering to address unmet needs in women\u2019s health","volume":"47","author":"Oyen","year":"2022","journal-title":"MRS Bull."},{"key":"10.1016\/j.jconrel.2025.114028_bb0050","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jconrel.2025.01.067","article-title":"Harnessing innovative drug delivery technologies for women\u2019s health","volume":"379","author":"Labouta","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114028_bb0055","doi-asserted-by":"crossref","DOI":"10.2174\/0122117385339882241206095441","article-title":"Advancements in nanoparticle-based targeted drug delivery systems for breast cancer","author":"Kunte","year":"2025","journal-title":"Pharm. Nanotechnol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2025.114504","article-title":"CD-44 targeted nanoparticles for combination therapy in an in vitro model of triple-negative breast cancer: targeting the tumour inside out","volume":"249","author":"Gomez-Pastor","year":"2025","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.jconrel.2025.114028_bb0065","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/21691401.2025.2462333","article-title":"An integrated in vitro and in silico approach to assess targeted cytotoxicity against MDA-MB-231 triple-negative breast cancer cells with Psidium guajava peel-derived chitosan nanoparticles","volume":"53","author":"Udappusamy","year":"2025","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104653","article-title":"Revolutionizing prostate cancer therapy: artificial intelligence - based nanocarriers for precision diagnosis and treatment","volume":"208","author":"Shirzad","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0075","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1021\/acs.molpharmaceut.4c01440","article-title":"Docetaxel-loaded electrospun nanofibrous mats for local chemotherapy targeting positive surgical margins in prostate cancer","volume":"22","author":"Li","year":"2025","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2025.114028_bb0080","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.drudis.2012.10.003","article-title":"Three-dimensional cell culture: the missing link in drug discovery","volume":"18","author":"Breslin","year":"2013","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2025.114028_bb0085","doi-asserted-by":"crossref","first-page":"1110551","DOI":"10.3389\/fcell.2023.1110551","article-title":"Large animal models in the study of gynecological diseases","volume":"11","author":"Cui","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0090","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3390\/pharmaceutics16111475","article-title":"The application of nano drug delivery systems in female upper genital tract disorders","volume":"16","author":"Van Staden","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2025.114028_bb0095","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.3390\/cancers14184500","article-title":"Current approaches to the management of patients with endometrial cancer","volume":"14","author":"Kalampokas","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.jconrel.2025.114028_bb0100","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1006\/gyno.2001.6291","article-title":"DNA methylation and ovarian cancer. I. Analysis of CpG island hypermethylation in human ovarian cancer using differential methylation hybridization","volume":"82","author":"Ahluwalia","year":"2001","journal-title":"Gynecol. Oncol."},{"issue":"Suppl. 2","key":"10.1016\/j.jconrel.2025.114028_bb0105","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/ijgo.12617","article-title":"Pathology of cancers of the female genital tract including molecular pathology","volume":"143","author":"Prat","year":"2018","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"10.1016\/j.jconrel.2025.114028_bb0110","doi-asserted-by":"crossref","DOI":"10.1093\/g3journal\/jkab392","article-title":"Identification of condition-specific biomarker systems in uterine cancer","volume":"12","author":"Hickman","year":"2022","journal-title":"G3 (Bethesda)"},{"key":"10.1016\/j.jconrel.2025.114028_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11111665","article-title":"Unique molecular features in high-risk histology endometrial cancers","volume":"11","author":"Pandita","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jconrel.2025.114028_bb0120","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1002\/cncr.32802","article-title":"Annual report to the nation on the status of cancer, part I: national cancer statistics","volume":"126","author":"Henley","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2025.114028_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115151","article-title":"Targeted drug conjugate systems for ovarian cancer chemotherapy","volume":"165","author":"Ogundipe","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.jconrel.2025.114028_bb0130","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1097\/CAD.0000000000000518","article-title":"CXCR4 blockade with AMD3100 enhances Taxol chemotherapy to limit ovarian cancer cell growth","volume":"28","author":"Reeves","year":"2017","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.jconrel.2025.114028_bb0135","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11864-025-01301-z","article-title":"Gynecologic cancer screening and prevention: state of the science and practice","volume":"26","author":"Tran","year":"2025","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0140","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3390\/nano11041048","article-title":"Polymeric nanoparticle delivery of combination therapy with synergistic effects in ovarian cancer","volume":"11","author":"Levit","year":"2021","journal-title":"Nanomaterials (Basel)"},{"key":"10.1016\/j.jconrel.2025.114028_bb0145","first-page":"126","article-title":"Ovarian cancer screening","volume":"36","author":"Neesham","year":"2007","journal-title":"Aust. Fam. Physician"},{"key":"10.1016\/j.jconrel.2025.114028_bb0150","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1136\/jmg-2024-110390","article-title":"The NHS England Jewish BRCA Testing Programme: overview after first year of implementation (2023-2024)","volume":"62","author":"Torr","year":"2025","journal-title":"J. Med. Genet."},{"issue":"2025","key":"10.1016\/j.jconrel.2025.114028_bb0155","first-page":"10","article-title":"Cancer statistics","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.jconrel.2025.114028_bb0160","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s13224-018-1102-z","article-title":"George papanicolaou (1883-1962): discoverer of the pap smear","volume":"68","author":"Chandrasekhar","year":"2018","journal-title":"J. Obstet. Gynaecol. India"},{"key":"10.1016\/j.jconrel.2025.114028_bb0165","series-title":"Global Strategy to Accelerate the Elimination of Cervical Cancer as a Public Problem","author":"W.H. Organization","year":"2025"},{"key":"10.1016\/j.jconrel.2025.114028_bb0170","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1056\/NEJMoa1917338","article-title":"HPV vaccination and the risk of invasive cervical cancer","volume":"383","author":"Lei","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2025.114028_bb0175","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s11864-025-01298-5","article-title":"Updates in hormone replacement therapy for survivors of gynecologic cancers","volume":"26","author":"Gorman","year":"2025","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.jogoh.2024.102902","article-title":"Barriers to prescription of hormonal contraception and hormone replacement therapy in gynecological cancer survivors: results of a survey and literature review","volume":"54","author":"Teves","year":"2025","journal-title":"J. Gynecol. Obstet. Hum. Reprod."},{"key":"10.1016\/j.jconrel.2025.114028_bb0185","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1093\/jnci\/djaf021","article-title":"Human papillomavirus-related squamous cell carcinomas after blood or marrow transplantation-a BMTSS report","volume":"117","author":"Holmqvist","year":"2025","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jconrel.2025.114028_bb0190","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ygyno.2024.12.002","article-title":"Prevalence and impact of vulvar lesions diagnosed prior to vulvar squamous cell carcinoma: a population-based cohort study","volume":"192","author":"Voss","year":"2025","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0195","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1200\/JCO.24.01071","article-title":"Advances in vulvar cancer biology and management","volume":"43","author":"Chehade","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0200","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0033-8389(01)00013-6","article-title":"Imaging of cancer of the endometrium","volume":"40","author":"Ascher","year":"2002","journal-title":"Radiol. Clin. North Am."},{"key":"10.1016\/j.jconrel.2025.114028_bb0205","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ijgo.14923","article-title":"Endometrial cancer staging subcommittee, FIGO staging of endometrial cancer: 2023","volume":"162","author":"Berek","year":"2023","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"10.1016\/j.jconrel.2025.114028_bb0210","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.prro.2022.09.002","article-title":"Radiation therapy for endometrial cancer: an american society for radiation oncology clinical practice guideline","volume":"13","author":"Harkenrider","year":"2023","journal-title":"Pract. Radiat. Oncol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0215","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijgo.2009.02.012","article-title":"Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium","volume":"105","author":"Pecorelli","year":"2009","journal-title":"Int. J. Gynaecol. Obstet."},{"issue":"Suppl. 1","key":"10.1016\/j.jconrel.2025.114028_bb0235","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/ijgo.13867","article-title":"Cancer of the vagina: 2021 update","volume":"155","author":"Adams","year":"2021","journal-title":"Int. J. Gynaecol. Obstet."},{"issue":"Suppl. 1","key":"10.1016\/j.jconrel.2025.114028_bb0240","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/ijgo.13878","article-title":"Cancer of the ovary, fallopian tube, and peritoneum: 2021 update","volume":"155","author":"Berek","year":"2021","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"10.1016\/j.jconrel.2025.114028_bb0225","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ijgo.12749","article-title":"Revised FIGO staging for carcinoma of the cervix uteri","volume":"145","author":"Bhatla","year":"2019","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"10.1016\/j.jconrel.2025.114028_bb0220","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ygyno.2018.10.026","article-title":"Validation of the 2018 FIGO cervical cancer staging system","volume":"152","author":"Matsuo","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0230","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijgo.2008.12.015","article-title":"Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia","volume":"105","author":"F.C.o.G. Oncology","year":"2009","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"10.1016\/j.jconrel.2025.114028_bb0245","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.soncn.2019.02.002","article-title":"Endometrial cancer: an overview of pathophysiology, management, and care","volume":"35","author":"Passarello","year":"2019","journal-title":"Semin. Oncol. Nurs."},{"issue":"Suppl. 1","key":"10.1016\/j.jconrel.2025.114028_bb0250","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1097\/PGP.0000000000000518","article-title":"Endometrial carcinoma diagnosis: use of FIGO grading and genomic subcategories in clinical practice: recommendations of the International Society of Gynecological Pathologists","volume":"38","author":"Soslow","year":"2019","journal-title":"Int. J. Gynecol. Pathol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0255","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1200\/JCO.2012.48.2596","article-title":"Type I and II endometrial cancers: have they different risk factors?","volume":"31","author":"Setiawan","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0260","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(15)00130-0","article-title":"Endometrial cancer","volume":"387","author":"Morice","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2025.114028_bb0265","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1080\/15548627.2020.1752548","article-title":"Autophagy in the physiological endometrium and cancer","volume":"17","author":"Devis-Jauregui","year":"2021","journal-title":"Autophagy"},{"key":"10.1016\/j.jconrel.2025.114028_bb0270","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/diagnostics7010012","article-title":"Subtypes of ovarian cancer and ovarian cancer screening","volume":"7","author":"Koshiyama","year":"2017","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.jconrel.2025.114028_bb0275","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1002\/cncr.29995","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy","volume":"122","author":"Matulonis","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2025.114028_bb0280","first-page":"519","article-title":"BRCA mutation in ovarian cancer: testing, implications and treatment considerations, Ther Adv","volume":"9","author":"Neff","year":"2017","journal-title":"Med. Oncol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0285","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1200\/JCO.21.02506","article-title":"TP53 sequencing and p53 immunohistochemistry predict outcomes when bevacizumab is added to frontline chemotherapy in endometrial cancer: An NRG oncology\/gynecologic oncology group study","volume":"40","author":"Thiel","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0290","doi-asserted-by":"crossref","first-page":"8713","DOI":"10.1073\/pnas.0803379105","article-title":"Drug-sensitive FGFR2 mutations in endometrial carcinoma","volume":"105","author":"Dutt","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2025.114028_bb0295","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/807849","article-title":"The oncoplacental gene placenta-specific protein 1 is highly expressed in endometrial tumors and cell lines","volume":"2013","author":"Devor","year":"2013","journal-title":"Obstet. Gynecol. Int."},{"key":"10.1016\/j.jconrel.2025.114028_bb0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0244558","article-title":"DACH1 mutation frequency in endometrial cancer is associated with high tumor mutation burden","volume":"15","author":"Riggs","year":"2020","journal-title":"PloS One"},{"key":"10.1016\/j.jconrel.2025.114028_bb0305","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11113114","article-title":"Endometrial Cancer and BRCA mutations: a systematic review","volume":"11","author":"Gasparri","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jconrel.2025.114028_bb0310","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3390\/cells13040345","article-title":"Complexity of the genetic background of oncogenesis in ovarian cancer-genetic instability and clinical implications","volume":"13","author":"Murawski","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.jconrel.2025.114028_bb0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1476-5829.2007.00142.x","article-title":"Cisplatin: a review of toxicities and therapeutic applications","volume":"6","author":"Barabas","year":"2008","journal-title":"Vet. Comp. Oncol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0335","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S1359-6349(15)70005-4","article-title":"Limitations to the use of carboplatin-based therapy in advanced ovarian cancer","volume":"12","author":"Fotopoulou","year":"2014","journal-title":"EJC Suppl."},{"key":"10.1016\/j.jconrel.2025.114028_bb0340","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2478\/raon-2019-0018","article-title":"Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy","volume":"53","author":"Makovec","year":"2019","journal-title":"Radiol. Oncol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0345","first-page":"2340","article-title":"Distribution and disposition of platinum following intravenous administration of cis-diamminedichloroplatinum(II) (NSC 119875) to dogs","volume":"36","author":"Litterst","year":"1976","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2025.114028_bb0350","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1177\/41.7.8515048","article-title":"A histochemical approach to the mechanism of action of cisplatin and its analogues","volume":"41","author":"Aggarwal","year":"1993","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.jconrel.2025.114028_bb0355","article-title":"Cisplatin and oxaliplatin: our current understanding of their actions","volume":"18","author":"Riddell","year":"2018","journal-title":"Met. Ions Life Sci."},{"key":"10.1016\/j.jconrel.2025.114028_bb0360","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Gynecologic oncology, phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0365","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.1200\/JCO.2005.19.638","article-title":"Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors","volume":"23","author":"Kondagunta","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0370","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1200\/JCO.2009.22.4725","article-title":"Efficacy of neoadjuvant cisplatin in triple-negative breast cancer","volume":"28","author":"Silver","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0375","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.1996.14.7.2101","article-title":"Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer","volume":"14","author":"Kemp","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0380","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1517\/14656566.4.6.889","article-title":"Toxicity of platinum compounds","volume":"4","author":"Hartmann","year":"2003","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.jconrel.2025.114028_bb0385","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ica.2012.01.028","article-title":"Understanding how the platinum anticancer drug carboplatin works: from the bottle to the cell","volume":"389","author":"Di Pasqua","year":"2012","journal-title":"Inorg. Chim. Acta"},{"key":"10.1016\/j.jconrel.2025.114028_bb0390","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/jnci\/81.19.1464","article-title":"Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin","volume":"81","author":"Mangioni","year":"1989","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jconrel.2025.114028_bb0395","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3109\/02841868909111182","article-title":"A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. The Swons Gynaecological Cancer Group","volume":"28","author":"Adams","year":"1989","journal-title":"Acta Oncol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0400","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2024.35.e76","article-title":"A retrospective study of dose-dense paclitaxel and carboplatin plus bevacizumab as first-line treatment of advanced epithelial ovarian cancer","volume":"35","author":"Komazaki","year":"2024","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0405","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","article-title":"Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer","volume":"23","author":"Gradishar","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0410","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1091\/mbc.e14-04-0916","article-title":"How Taxol\/paclitaxel kills cancer cells","volume":"25","author":"Weaver","year":"2014","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.jconrel.2025.114028_bb0415","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.clon.2014.10.001","article-title":"Dose-dense paclitaxel in advanced ovarian cancer","volume":"27","author":"Kumar","year":"2015","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"key":"10.1016\/j.jconrel.2025.114028_bb0420","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.23.02132","article-title":"Durvalumab plus carboplatin\/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial","volume":"42","author":"Westin","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0425","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/FPC.0b013e32833ffb56","article-title":"Doxorubicin pathways: pharmacodynamics and adverse effects","volume":"21","author":"Thorn","year":"2011","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.jconrel.2025.114028_bb0430","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10557-016-6711-0","article-title":"Anthracycline chemotherapy and cardiotoxicity","volume":"31","author":"McGowan","year":"2017","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.jconrel.2025.114028_bb0435","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2004.09.046","article-title":"Role of pegylated liposomal doxorubicin in ovarian cancer","volume":"96","author":"Thigpen","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0440","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/17512433.2019.1573668","article-title":"Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review","volume":"12","author":"Megias-Vericat","year":"2019","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0315","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1097\/01.pas.0000213428.61374.06","article-title":"Utility of immunohistochemistry in predicting microsatellite instability in endometrial carcinoma","volume":"31","author":"Modica","year":"2007","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0320","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1002\/ijc.35368","article-title":"Acceptability and somatic mutations in cervicovaginal self-sampling for early endometrial cancer detection in women with lynch syndrome","volume":"156","author":"Peremiquel-Trillas","year":"2025","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jconrel.2025.114028_bb0325","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/den.13702","article-title":"Colorectal cancer screening in lynch syndrome: indication, techniques and future perspectives","volume":"33","author":"Perrod","year":"2021","journal-title":"Dig. Endosc."},{"key":"10.1016\/j.jconrel.2025.114028_bb0445","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.ygyno.2013.09.030","article-title":"Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery","volume":"131","author":"Muraji","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0450","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1016\/j.bjps.2021.03.038","article-title":"The combined use of pedicled profunda artery perforator and bilateral gracilis flaps for pelvic reconstruction: a cohort study","volume":"74","author":"Sharp","year":"2021","journal-title":"J. Plast. Reconstr. Aesthet. Surg."},{"key":"10.1016\/j.jconrel.2025.114028_bb0455","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/17425247.2020.1822321","article-title":"Surface-modified polymeric nanoparticles for drug delivery to cancer cells","volume":"18","author":"Ahmed","year":"2021","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2025.114028_bb0460","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/bjs.4857","article-title":"Primary rectus abdominis myocutaneous flap for repair of perineal and vaginal defects after extended abdominoperineal resection","volume":"92","author":"Bell","year":"2005","journal-title":"Br. J. Surg."},{"key":"10.1016\/j.jconrel.2025.114028_bb0465","doi-asserted-by":"crossref","first-page":"4759","DOI":"10.7314\/APJCP.2014.15.12.4759","article-title":"Radiotherapy for ovarian cancers - redefining the role","volume":"15","author":"Rai","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.jconrel.2025.114028_bb0470","series-title":"Seminars in Radiation Oncology","first-page":"168","article-title":"Integrating radiation into the management of vulvar cancer","author":"Barnes","year":"2006"},{"key":"10.1016\/j.jconrel.2025.114028_bb0475","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.critrevonc.2004.05.003","article-title":"The role of chemotherapy in locally advanced, metastatic and recurrent cervical cancer","volume":"52","author":"Tambaro","year":"2004","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0480","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.ejso.2006.03.037","article-title":"Management of cervical cancer","volume":"32","author":"Kesic","year":"2006","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0485","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/s41598-022-05126-w","article-title":"Increased risk of secondary bladder cancer after radiation therapy for endometrial cancer","volume":"12","author":"Wen","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2025.114028_bb0490","doi-asserted-by":"crossref","first-page":"24623","DOI":"10.1038\/s41598-024-74840-4","article-title":"Association between radiation therapy for primary endometrial cancer and risk of second primary malignancies: a retrospective cohort study","volume":"14","author":"Wang","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2025.114028_bb0495","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1634\/theoncologist.2016-0062","article-title":"Chemotherapy for endometrial cancer in adjuvant and advanced disease settings","volume":"21","author":"Bestvina","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.jconrel.2025.114028_bb0500","doi-asserted-by":"crossref","first-page":"138","DOI":"10.4103\/jrpp.JRPP_20_128","article-title":"Effectiveness of megestrol for the treatment of patients with atypical endometrial hyperplasia or endometrial endometrioid adenocarcinoma (stage IA, well differentiated)","volume":"10","author":"Akhavan","year":"2021","journal-title":"J. Res. Pharm. Pract."},{"key":"10.1016\/j.jconrel.2025.114028_bb0505","first-page":"232","article-title":"New concepts for an old problem: the diagnosis of endometrial hyperplasia","volume":"23","author":"Sanderson","year":"2017","journal-title":"Hum. Reprod. Update"},{"key":"10.1016\/j.jconrel.2025.114028_bb0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100604","article-title":"Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines","volume":"8","author":"Zarkavelis","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.jconrel.2025.114028_bb0515","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1200\/JCO.20.01076","article-title":"Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG oncology\/GOG0209)","volume":"38","author":"Miller","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0520","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1002\/jcp.26289","article-title":"Molecular mechanisms of drug resistance in ovarian cancer","volume":"233","author":"Norouzi-Barough","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0525","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12943-024-01967-3","article-title":"Drug resistance in ovarian cancer: from mechanism to clinical trial","volume":"23","author":"Wang","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jconrel.2025.114028_bb0530","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS6108","volume":"38","author":"Westin","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0535","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.19.01598","article-title":"Phase IB\/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors","volume":"38","author":"Taylor","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0540","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2025.114028_bb0545","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil(R)\u2014the first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114028_bb0550","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41416-020-0916-5","article-title":"First-in-human study of the PARP\/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor","volume":"123","author":"Plummer","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2025.114028_bb0555","series-title":"708\u00a0A Phase 1\/2 Study of Rinatabart Sesutecan (PRO1184), a Novel Folate Receptor Alpha-directed Antibody-drug Conjugate, in Patients With Locally Advanced and\/or Metastatic Solid Tumors","author":"Call","year":"2025"},{"key":"10.1016\/j.jconrel.2025.114028_bb0560","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2017.28.e26","article-title":"An open-label, multicenter, phase I trial of a cremophor-free, polymeric micelle formulation of paclitaxel combined with carboplatin as a first-line treatment for advanced ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG-3016)","volume":"28","author":"Lee","year":"2017","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0565","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S1470-2045(19)30326-2","article-title":"NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2\u20133, randomised, controlled trial","volume":"20","author":"Bonvalot","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0570","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40824-020-00190-7","article-title":"Recent advances in polymeric drug delivery systems","volume":"24","author":"Sung","year":"2020","journal-title":"Biomater. Res."},{"key":"10.1016\/j.jconrel.2025.114028_bb0575","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1021\/acs.chemrev.3c00705","article-title":"Polymeric nanoparticles for drug delivery","volume":"124","author":"Beach","year":"2024","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jconrel.2025.114028_bb0580","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biomaterials.2017.09.002","article-title":"Molecular insights for the biological interactions between polyethylene glycol and cells","volume":"147","author":"Xu","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2025.114028_bb0585","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jconrel.2022.09.031","article-title":"Polyethylene glycol (PEG): the nature, immunogenicity, and role in the hypersensitivity of PEGylated products","volume":"351","author":"Ibrahim","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114028_bb0590","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jconrel.2022.09.002","article-title":"Stealth nanoparticles in oncology: facing the PEG dilemma","volume":"351","author":"Zalba","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114028_bb0595","first-page":"393","article-title":"Everolimus-eluting stents in interventional cardiology","volume":"8","author":"Townsend","year":"2012","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.jconrel.2025.114028_bb0600","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jconrel.2021.10.008","article-title":"Novel polymer-based system for intrauterine delivery of everolimus for anti-cancer applications","volume":"339","author":"Melendez","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114028_bb0605","series-title":"Dense Star Polymers Having Core, Core Branches, Terminal Groups","author":"Tomalia","year":"1985"},{"key":"10.1016\/j.jconrel.2025.114028_bb0610","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13036-022-00298-5","article-title":"Dendrimer-based drug delivery systems: history, challenges, and latest developments","volume":"16","author":"Wang","year":"2022","journal-title":"J. Biol. Eng."},{"key":"10.1016\/j.jconrel.2025.114028_bb0615","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1021\/ja01856a061","article-title":"Molecular size distribution in three dimensional polymers. I. Gelation1","volume":"63","author":"Flory","year":"2002","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2025.114028_bb0620","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1055\/s-1978-24702","article-title":"Cascade-chain-like and nonskid-chain-like syntheses of molecular cavity topologies","volume":"1978","author":"Buhleier","year":"1978","journal-title":"Synthesis-Stuttgart"},{"key":"10.1016\/j.jconrel.2025.114028_bb0625","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1002\/pola.10301","article-title":"Discovery of dendrimers and dendritic polymers: a brief historical perspective","volume":"40","author":"Tomalia","year":"2002","journal-title":"J. Polym. Sci. A"},{"key":"10.1016\/j.jconrel.2025.114028_bb0630","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1039\/B901839P","article-title":"Biomedical applications of dendrimers: a tutorial","volume":"40","author":"Mintzer","year":"2011","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.jconrel.2025.114028_bb0635","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/pol.20240933","article-title":"Cholesterol-conjugated PAMAM dendrimers: enhancing stability, drug delivery efficiency, and in vitro anticancer performance","volume":"63","author":"Luu","year":"2024","journal-title":"J. Polym. Sci."},{"key":"10.1016\/j.jconrel.2025.114028_bb0640","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12121175","article-title":"BCS class IV Oral drugs and absorption windows: regional-dependent intestinal permeability of furosemide","volume":"12","author":"Markovic","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2025.114028_bb0645","series-title":"Dendrimers: A Review on Synthetic Approaches, Issue: 3","author":"Vivek Gupta","year":"2015"},{"key":"10.1016\/j.jconrel.2025.114028_bb0650","doi-asserted-by":"crossref","first-page":"506","DOI":"10.18632\/oncotarget.13471","article-title":"Is the positivity of estrogen receptor or progesterone receptor different between type 1 and type 2 endometrial cancer?","volume":"8","author":"Shen","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2025.114028_bb0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioadv.2022.213047","article-title":"Lapatinib- and fulvestrant-PAMAM dendrimer conjugates promote apoptosis in chemotherapy-induced senescent breast cancer cells with different receptor status","volume":"140","author":"Lewinska","year":"2022","journal-title":"Biomater. Adv."},{"key":"10.1016\/j.jconrel.2025.114028_bb0660","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jconrel.2018.09.017","article-title":"PLGA: from a classic drug carrier to a novel therapeutic activity contributor","volume":"289","author":"Chereddy","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114028_bb0665","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14122728","article-title":"PLGA-based nanomedicine: history of advancement and development in clinical applications of multiple diseases","volume":"14","author":"Alsaab","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2025.114028_bb0670","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1021\/acs.molpharmaceut.9b01188","article-title":"Effect of manufacturing variables and raw materials on the composition-equivalent PLGA microspheres for 1-month controlled release of leuprolide","volume":"17","author":"Zhou","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2025.114028_bb0675","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/AOG.0000000000005444","article-title":"Medical management of ovarian endometriomas: a systematic review and meta-analysis","volume":"143","author":"Eberle","year":"2024","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0680","first-page":"33","article-title":"Clinical development of the GnRH agonist leuprolide acetate depot","volume":"4","author":"Chwalisz","year":"2023","journal-title":"F. S. Rep."},{"key":"10.1016\/j.jconrel.2025.114028_bb0685","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1080\/02652048.2022.2100934","article-title":"Advances in encapsulating gonadotropin-releasing hormone agonists for controlled release: a review","volume":"39","author":"Bazybek","year":"2022","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.jconrel.2025.114028_bb0690","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jconrel.2023.06.016","article-title":"Mechanistic evaluation of the initial burst release of leuprolide from spray-dried PLGA microspheres","volume":"361","author":"Schutzman","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114028_bb0695","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1186\/s12951-024-02744-6","article-title":"Tumor targeting peptide TMTP1 modified antigen capture Nano-vaccine combined with chemotherapy and PD-L1 blockade effectively inhibits growth of ovarian cancer","volume":"22","author":"Zhou","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0700","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/17568919.2025.2458457","article-title":"Dual delivery of metformin and Y15 from a PLGA scaffold for the treatment of platinum-resistant ovarian cancer","volume":"17","author":"Jordan","year":"2025","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.jconrel.2025.114028_bb0705","first-page":"1","article-title":"In vitro characterization of six month dosage forms for a GnRH antagonist","volume":"2014","author":"D\u2019Souza","year":"2014","journal-title":"Adv. Pharm."},{"key":"10.1016\/j.jconrel.2025.114028_bb0710","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jconrel.2023.11.043","article-title":"Impact of the physical-chemical properties of poly(lactic acid)-poly(ethylene glycol) polymeric nanoparticles on biodistribution","volume":"365","author":"Jackman","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114028_bb0715","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1021\/acs.chemrev.5b00346","article-title":"Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release","volume":"116","author":"Kamaly","year":"2016","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jconrel.2025.114028_bb0720","doi-asserted-by":"crossref","first-page":"25124","DOI":"10.1021\/acsomega.4c02510","article-title":"Dual functional antibacterial-antioxidant core\/shell alginate\/poly(epsilon-caprolactone) nanofiber membrane: a potential wound dressing","volume":"9","author":"Norouzi","year":"2024","journal-title":"ACS Omega"},{"key":"10.1016\/j.jconrel.2025.114028_bb0725","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfa.2024.134873","article-title":"Formulation of polycaprolactone meshes by melt electrospinning for controlled release of daunorubicin in tumour therapy","volume":"699","author":"Obeid","year":"2024","journal-title":"Colloids Surf. A"},{"key":"10.1016\/j.jconrel.2025.114028_bb0730","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/0032-3861(81)90137-3","article-title":"Preparation and properties of poly(valerolactone)","volume":"22","author":"Aubin","year":"1981","journal-title":"Polymer"},{"key":"10.1016\/j.jconrel.2025.114028_bb0735","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1016\/j.xphs.2021.03.009","article-title":"Poly(delta-valerolactone-co-allyl-delta-valerolactone) cross-linked microparticles: formulation, characterization and biocompatibility","volume":"110","author":"Bao","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2025.114028_bb0740","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.addr.2009.10.004","article-title":"HPMA copolymers: origins, early developments, present, and future","volume":"62","author":"Kopecek","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2025.114028_bb0745","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/mabi.201200353","article-title":"Synthesis of long-circulating, backbone degradable HPMA copolymer-doxorubicin conjugates and evaluation of molecular-weight-dependent antitumor efficacy","volume":"13","author":"Pan","year":"2013","journal-title":"Macromol. Biosci."},{"key":"10.1016\/j.jconrel.2025.114028_bb0750","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ijpharm.2013.06.046","article-title":"Biodegradable multiblock poly(N-2-hydroxypropyl)methacrylamide gemcitabine and paclitaxel conjugates for ovarian cancer cell combination treatment","volume":"454","author":"Larson","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2025.114028_bb0755","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ejpb.2013.11.008","article-title":"Combination cytotoxicity of backbone degradable HPMA copolymer gemcitabine and platinum conjugates toward human ovarian carcinoma cells","volume":"87","author":"Duangjai","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2025.114028_bb0760","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122801","article-title":"Liposomes-enabled cancer chemoimmunotherapy","volume":"313","author":"Zhang","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2025.114028_bb0765","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00280-014-2514-9","article-title":"Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (Caelyx(R))","volume":"74","author":"Boers-Sonderen","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0770","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1006\/gyno.2002.6830","article-title":"Liposomal doxorubicin for treatment of metastatic chemorefractory vulvar adenocarcinoma","volume":"87","author":"Huang","year":"2002","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0775","article-title":"The prognosis of cancer patients undergoing liposomal doxorubicin-based chemotherapy: a systematic review and meta-analysis","volume":"100","author":"Zhang","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jconrel.2025.114028_bb0780","article-title":"Thirty years from FDA approval of pegylated liposomal doxorubicin (Doxil\/Caelyx): an updated analysis and future perspective","volume":"4","author":"Gabizon","year":"2025","journal-title":"BMJ Oncol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0785","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1208\/s12249-017-0877-z","article-title":"Mixed liposome approach for ratiometric and sequential delivery of paclitaxel and gemcitabine","volume":"19","author":"Liu","year":"2018","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2025.114028_bb0790","first-page":"7497","article-title":"Pegylated liposomal-paclitaxel induces ovarian cancer cell apoptosis via TNF-induced ERK\/AKT signaling pathway","volume":"17","author":"Qi","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.jconrel.2025.114028_bb0795","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10555-006-9001-7","article-title":"Role of tumor-associated macrophages in tumor progression and invasion","volume":"25","author":"Mantovani","year":"2006","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.jconrel.2025.114028_bb0800","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.583084","article-title":"Tumor-associated macrophages in tumor immunity","volume":"11","author":"Pan","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0805","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125334","article-title":"Follicle-stimulating hormone peptide-conjugated liposomes in the treatment of epithelial ovarian cancer through the induction of M2-to-M1 macrophage repolarization","volume":"672","author":"Hu","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2025.114028_bb0810","doi-asserted-by":"crossref","DOI":"10.1016\/j.arabjc.2021.103576","article-title":"Formulation and characterization of a novel anti-human endometrial cancer supplement by gold nanoparticles green-synthesized using L. Leaf aqueous extract","volume":"15","author":"Zhu","year":"2022","journal-title":"Arab. J. Chem."},{"key":"10.1016\/j.jconrel.2025.114028_bb0815","doi-asserted-by":"crossref","first-page":"6661","DOI":"10.2147\/IJN.S329341","article-title":"Enhancing of Nanocatalyst-driven chemodynaminc therapy for endometrial cancer cells through inhibition of PINK1\/Parkin-mediated mitophagy","volume":"16","author":"Gong","year":"2021","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2025.114028_bb0820","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.2147\/IJN.S373147","article-title":"Zinc oxide particles can cause ovarian toxicity by oxidative stress in female mice model","volume":"17","author":"Xu","year":"2022","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2025.114028_bb0825","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12934-025-02656-6","article-title":"Biogenesis, characterization, and applications of Spirulina selenium nanoparticles","volume":"24","author":"Yassein","year":"2025","journal-title":"Microb. Cell Fact."},{"key":"10.1016\/j.jconrel.2025.114028_bb0830","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s11671-025-04212-y","article-title":"Bio-fabricated silver nanoparticles: therapeutic evaluation as a potential nanodrug against cervical and liver cancer cells","volume":"20","author":"Ahamad","year":"2025","journal-title":"Discov. Nano"},{"key":"10.1016\/j.jconrel.2025.114028_bb0835","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s12032-024-02593-1","article-title":"Study of the effect of zinc oxide, selenium, and silver nanoparticles on the expression level of oxidative stress-associated genes in ovarian cancer","volume":"42","author":"Irannejad","year":"2025","journal-title":"Med. Oncol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0840","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.174751","article-title":"Targeted drug delivery in cervical cancer: current perspectives","volume":"917","author":"Ghosh","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0845","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.3892\/ijo.2015.2937","article-title":"Autophagy inhibition enhances sensitivity of endometrial carcinoma cells to paclitaxel","volume":"46","author":"Liu","year":"2015","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0850","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.3892\/ijo.2012.1600","article-title":"Differential sensitivity to paclitaxel-induced apoptosis and growth suppression in paclitaxel-resistant cell lines established from HEC-1 human endometrial adenocarcinoma cells","volume":"41","author":"Tanaka","year":"2012","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0860","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1517\/17425247.2010.502560","article-title":"Zinc oxide nanoparticles for selective destruction of tumor cells and potential for drug delivery applications","volume":"7","author":"Rasmussen","year":"2010","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2025.114028_bb0865","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1021\/cr300014x","article-title":"Introduction to metal-organic frameworks","volume":"112","author":"Zhou","year":"2012","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jconrel.2025.114028_bb0870","doi-asserted-by":"crossref","first-page":"4068","DOI":"10.1038\/s41467-020-17755-8","article-title":"Understanding the diversity of the metal-organic framework ecosystem","volume":"11","author":"Moosavi","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.114028_bb0875","article-title":"PEG-functionalized UiO-66 MOFs for targeted vincristine delivery: enhanced cytotoxicity in breast and ovarian cancer cell lines, cancer","volume":"16","author":"Sadeghi Jam","year":"2025","journal-title":"Nanotechnology"},{"key":"10.1016\/j.jconrel.2025.114028_bb0880","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2025.e42685","article-title":"Cisplatin-loaded UiO-66-NH(2) functionalized with folic acid enhances apoptotic activity and antiproliferative effects in MDA-MB-231 breast and A2780 ovarian cancer cells: an in vitro study","volume":"11","author":"Sadeghi Jam","year":"2025","journal-title":"Heliyon"},{"key":"10.1016\/j.jconrel.2025.114028_bb0885","doi-asserted-by":"crossref","DOI":"10.1007\/s42114-025-01242-z","article-title":"Biomimetic MOF nanoplatform for dual-targeted co-delivery of FAK inhibitor and bismuth to enhance cervical cancer radiosensitivity","volume":"8","author":"Chang","year":"2025","journal-title":"Adv. Compos. Hybrid Mater."},{"key":"10.1016\/j.jconrel.2025.114028_bb0890","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.semcancer.2021.03.032","article-title":"Exosomes and extracellular vesicles: rethinking the essential values in cancer biology","volume":"74","author":"Yokoi","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0895","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jconrel.2024.12.011","article-title":"Harnessing extracellular vesicle-mediated crosstalk between T cells and cancer cells for therapeutic applications","volume":"378","author":"Budayr","year":"2025","journal-title":"J. Control. Release"},{"issue":"2024","key":"10.1016\/j.jconrel.2025.114028_bb0900","article-title":"Exosome nanovesicles: biomarkers and new strategies for treatment of human diseases","volume":"5","author":"Xu","year":"2020","journal-title":"MedComm"},{"key":"10.1016\/j.jconrel.2025.114028_bb0905","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12951-025-03165-9","article-title":"Engineered CAF-cancer cell hybrid membrane biomimetic dual-targeted integrated platform for multi-dimensional treatment of ovarian cancer","volume":"23","author":"Yao","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0910","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.biomaterials.2018.08.016","article-title":"PEGylated tumor cell membrane vesicles as a new vaccine platform for cancer immunotherapy","volume":"182","author":"Ochyl","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2025.114028_bb0915","first-page":"4763","article-title":"Estrous cycle influences organ-specific metastasis of B16F10 melanoma cells","volume":"63","author":"Vantyghem","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2025.114028_bb0920","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0925","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s12094-022-02925-5","article-title":"Blockade of exosome release alters HER2 trafficking to the plasma membrane and gives a boost to Trastuzumab","volume":"25","author":"Hosseini","year":"2023","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.jconrel.2025.114028_bb0935","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jconrel.2024.05.035","article-title":"Efficient intracellular drug delivery by co-administration of two antibodies against cell adhesion molecule 1","volume":"371","author":"Hagiyama","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114028_bb0940","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1223","article-title":"FGFR2 mutations promote endometrial cancer progression through dual engagement of EGFR and Notch signalling pathways","volume":"13","author":"Dixit","year":"2023","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.jconrel.2025.114028_bb0945","doi-asserted-by":"crossref","DOI":"10.3390\/cells10051201","article-title":"Fibroblast growth factor receptors (FGFRs) and noncanonical partners in cancer signaling","volume":"10","author":"Ferguson","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.jconrel.2025.114028_bb0950","doi-asserted-by":"crossref","DOI":"10.3390\/gels8070393","article-title":"Chitosan: sources, processing and modification techniques","volume":"8","author":"Pellis","year":"2022","journal-title":"Gels"},{"key":"10.1016\/j.jconrel.2025.114028_bb0955","doi-asserted-by":"crossref","DOI":"10.1016\/j.rechem.2025.102115","article-title":"Synthesis of sap-functionalized Nano-chitosan for biomedical applications: apoptosis induction and tumor cell line growth inhibition","volume":"14","author":"Rahimi","year":"2025","journal-title":"Results Chem."},{"key":"10.1016\/j.jconrel.2025.114028_bb0960","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1007\/s43032-021-00529-y","article-title":"Animal models and alternatives in vaginal research: a comparative review","volume":"28","author":"McCracken","year":"2021","journal-title":"Reprod. Sci."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925006492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925006492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:19:49Z","timestamp":1778944789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925006492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":190,"alternative-id":["S0168365925006492"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.114028","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanocarrier drug delivery systems for gynecological cancer therapeutics","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.114028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114028"}}